Prognose

Das durchschnittliche Kursziel der Analysten beträgt +1,75€(−3,31%). Der Median liegt bei +1,75€(−3,31%).

Kaufen	4
Halten	0
Verkaufen	0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025
WILMINGTON, Del. , April 21, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, today announced that it will participate in an H.C.» Mehr auf prnewswire.com
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE
Investment to support initiation of HOPE's network of clinics to treat suicidal depression and PTSD with ketamine, TMS and other modalities MIAMI , April 3, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq:NRXP), today announced signing of a term sheet with a global medical device manufacturer, as anticipated in the Company's recently filed annual report. The investor shares HOPE's vision of providing comprehensive interventional psychiatry treatments to patients around the world.» Mehr auf prnewswire.com
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics
Dura Medical, together with previously-announced acquisition of Neurospa TMS, will provide coverage throughout the West Coast of Florida Delivers a full range of precision psychiatry services for severe depression and PTSD, including Ketamine Therapy and Transcranial Magnetic Stimulation (TMS), to veteran and civilian patients Stephen Durand, founder of Dura, to serve as Director of Clinic Operations for HOPE in Florida MIAMI , March 31, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq: NRXP), today announced signing of a definitive Agreement to acquire Dura Medical (Dura), per the previously announced non-binding Letter of Intent. Dura, together with the previously announced Neurospa network, are anticipated to provide a comprehensive service offering to patients on Florida's west coast.» Mehr auf prnewswire.com

Unternehmenszahlen

Im letzten Quartal hatte BIG ROCKPAR einen Umsatz von 0,00€ und ein Nettoeinkommen von −8,72 Mio€

(EUR)	Dez. 2024	YOY
Umsatz	0,00	100,00%
Bruttoeinkommen	0,00	100,00%
Nettoeinkommen	−8,72 Mio	122,62%
EBITDA	−8,72 Mio	126,84%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+30,40 Mio€
Anzahl Aktien	16,92 Mio
52 Wochen-Hoch/Tief	+5,27€ - +0,96€
Dividenden	Nein
Beta	1,41
KGV (PE Ratio)	−0,86
KGWV (PEG Ratio)	+0,02
KBV (PB Ratio)	−0,93
KUV (PS Ratio)	0,00

Unternehmensprofil

NRX Pharmaceuticals, Inc. ist ein pharmazeutisches Unternehmen in der klinischen Phase und entwickelt neuartige Therapeutika für die Behandlung von Erkrankungen des zentralen Nervensystems und lebensbedrohlichen Lungenkrankheiten. Zu seinen Produkten gehören ZYESAMI, ein Prüfpräparat, das eine klinische Studie der Phase IIb/III zur Behandlung von COVID-19-bedingtem Atemversagen abgeschlossen hat, sowie die oralen Therapeutika NRX-100 und NRX-101 zur Behandlung bipolarer Depressionen bei Patienten mit akuter Suizidalität und subakuten Suizidgedanken und -verhaltensweisen. Das Unternehmen wurde im Jahr 2015 gegründet und hat seinen Sitz in Wilmington, Delaware.